Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

INO has been the subject of several other research reports. Maxim Group set a $8.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, May 10th. BidaskClub downgraded Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 6th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. Finally, HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 16th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $11.25.

Shares of INO opened at $5.43 on Wednesday. Inovio Pharmaceuticals has a 52-week low of $3.64 and a 52-week high of $7.00. The firm has a market capitalization of $481.27 million, a price-to-earnings ratio of -4.98 and a beta of 1.82.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.27. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. The firm had revenue of $24.45 million during the quarter, compared to the consensus estimate of $2.13 million. equities research analysts expect that Inovio Pharmaceuticals will post -1.07 earnings per share for the current year.

In other news, CFO Peter Kies sold 35,000 shares of Inovio Pharmaceuticals stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $4.44, for a total value of $155,400.00. Following the completion of the sale, the chief financial officer now directly owns 97,088 shares of the company’s stock, valued at approximately $431,070.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 9.40% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in shares of Inovio Pharmaceuticals by 36.6% during the second quarter. Bank of America Corp DE now owns 114,660 shares of the biopharmaceutical company’s stock worth $449,000 after purchasing an additional 30,740 shares during the period. BlackRock Inc. grew its stake in shares of Inovio Pharmaceuticals by 5.5% during the second quarter. BlackRock Inc. now owns 6,845,338 shares of the biopharmaceutical company’s stock worth $26,834,000 after purchasing an additional 356,105 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Inovio Pharmaceuticals by 8.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 445,846 shares of the biopharmaceutical company’s stock worth $1,748,000 after purchasing an additional 33,567 shares during the period. Levin Capital Strategies L.P. grew its stake in shares of Inovio Pharmaceuticals by 80.5% during the second quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 16,500 shares during the period. Finally, ARK Investment Management LLC grew its stake in shares of Inovio Pharmaceuticals by 79.8% during the second quarter. ARK Investment Management LLC now owns 1,194,657 shares of the biopharmaceutical company’s stock worth $4,683,000 after purchasing an additional 530,247 shares during the period. 31.53% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Article: Are analyst ratings accurate?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.